Synexus acquires HCTC
Synexus, the leading international clinical research site group backed by Lyceum Capital, has expanded its presence in South Africa with the acquisition of a specialist clinical trial site in Helderberg, Western Cape.
The site — Helderberg Clinical Trials Centre (HCTC) — will now be known as Synexus Helderberg Clinical Research Centre.
It is Synexus’ fourth dedicated research facility in South Africa and brings the company’s global site count to 24, including three new centres opened in the past six months.
Dr Graham Ellis, who founded HCTC in 1994, has been appointed medical director of the facility. He will remain centre manager and continue to lead the investigator and clinical team.
Christophe Berthoux, CEO of Synexus, said: “This is yet another development we have put in place to meet the increasing demands of the pharma industry for our high-quality professional services. Our order book is at a record high and continuing to grow.
“We have long recognised the vital role South Africa has to play in global clinical trials and this addition to our portfolio and continued investment in the region is testament to that.
“South Africa provides access to a large patient pool, excellent medical infrastructure and the training of medical staff at all levels is of a very high standard.
“There is also a high public awareness of the benefits of clinical trials which speeds up recruitment and overcomes the lengthy regulatory process. These are all key factors in ensuring the success of a clinical trial.”